Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments
NCT ID: NCT06562400
Last Updated: 2024-08-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
45 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-05-10
Study Completion Date
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary working hypothesis is that NON-responders to mAbs bear a dysfunction of the endocannabidiome system (eCBome), as suggested by pre-clinical and clinical data by our group.
They will be identified as patients showing a reduction of monthly migraine days \< 50% after three months of treatment.
The clinical, biochemical and neurofunctional impact of novel therapeutic approaches expected to interfere with eCBome will be evaluated in NON-responder patients
They will be identified as patients showing a reduction of monthly migraine days \< 50% after three months of treatment.
The clinical, biochemical and neurofunctional impact of novel therapeutic approaches expected to interfere with eCBome will be evaluated in NON-responder patients
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Searching for Novel Biological Phenotypes in Migraine Patients Resistant to Treatments
NCT06562413
Migraine Disorders
Chronic Migraine
Episodic Migraine
RECRUITING
Biochemical Profiling of Migraine Patients
NCT06549270
Migraine Disorders
Chronic Migraine
Episodic Migraine
RECRUITING
KETOMIGRAINE: Ketogenic Diet in Drug-resistant Chronic Migraineurs
NCT05313503
Chronic Migraine, Headache
UNKNOWN
NA
Psychological and Biological Markers of Refractory Migraine
NCT05046119
Migraine
UNKNOWN
Plasma Levels of CGRP and Expression of Specific microRNAs in Blood Cells of Episodic and Chronic Migraine Subjects
NCT04473976
Migraine
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Monoclonal antibodies directed against the calcitonin gene related peptide pathway (mAbs) have recently become available as the first targeted-therapy for migraine prevention. Despite their revolution in migraine therapy, clinical evidence demonstrated that nearly one-third of patients do not respond to mAbs. Even among Responders (namely those with a reduction in monthly migraine days - MMDs, of at least 50%), almost half still suffers from 8 residual MMDs or more.
There is therefore room for improvement, and understanding the pathophysiological mechanisms involved in these processes is mandatory to develop novel therapies and optimize treatment outcome.
Among several non-CGRP pathways, the eCBome may play a major role in migraine as it interacts with multiple pathways to modulate inflammation and pain.
Previous evidence showed that genes expression of eCBome system is altered in migraine patients.
Interestingly, it seems possible to normalize eCBome dysfunction in migraineurs, as demonstrated by the decrease of FAAH levels in chronic migraineurs with medication overuse who underwent a successful detoxification.
From a therapeutic point of view, a potential role for PEA in the termination of experimentally-induced migraine attack in humans and in the acute treatment of spontaneous attacks were published.
Polyunsaturated fatty acids (PUFAs) are other eCBome precursors involved in neuronal processes and anti-inflammatory properties. Data supports an interconnection between dietary n-3 PUFAs intake, also showing a protective action of high PUFAs intake in inflammation and neurodegenerative disease.
Another therapeutic weapon is represented by the ketogenic diet (KD), a "fat" diet that induces an increase in PUFAs. In migraine, KD reduced the frequency of migraine attacks when compared to a standard mediterranean diet in episodic migraine.
It may interfere with the eCBome at multiple levels (gut and brain) and via multiple mechanisms: i) increase in substrate availability; ii) improvement of cortical metabolism and hyperexcitability enhancing glutamate clearing from astrocytes; ii) modulation of neuro-inflammation.
Preliminary evidence also support a role for KD in treatment-resistant migraine, and in a small number of CM patients resistant to approved therapies, with preliminary data suggest a positive response. Its efficacy in patients who failed mAbs treatment is yet to be elucidated, though.
As intriguing data suggests the possibility to interfere with the eCBome via multiple modalities, ranging from PEA administration to dietary adaptations, it seems extremely interesting to identify an eCBome-dependent migraine phenotype and to test its performance in proof-of-concept therapeutic challenges.
The investigators intend to act on the alteration of microbiota through the ketogenic diet (KD) and on the alteration in endocannabinoids related lipids with PEA or PUFA supplementation. These therapeutic modalities are already available for clinical use and have a highly safe profile, easily ready to be used for improving health in a group of highly disabled patients.
The investigators will also try a concomitant therapy (mAbs + PEA / PUFA) in order to provide insights on the effect of a concomitant dual modulation (CGRP and eCBome system) in patients undergoing mAbs treatment.
Furthermore, a comprehensive biochemical set of potential biomarkers will be evaluated, including neuropeptides, microRNAs, inflammatory cytokines, kynurenine metabolites and brain cortical connectivity trough recording of HD- EEG and rs-fMRI. The biochemical and functional phenotyping will allow the identification of a multibiomarkers panel signature of migraine patients resisting to specifically targeted preventive treatments, potentially associated to the clinical response to treatments that targets different pathways.
Study design:
Patients will be enrolled among those receiving treatment with monoclonal antibodies against the calcitonin gene receptor peptide pathway (mAbs) at the clinic of IRCCS Mondino Institute (Pavia) and Neurology Department of the University of L'Aquila (Avezzano).
The following groups will be identified:
* NON-responder group: patients who show a reduction \< 50% of MMDs after 3 to 6 months of mAbs treatment compared to baseline
* Partial Responder: patients who show a reduction \> / = 50% of MMDs after 3 to 6 months of treatment compared to baseline, but still having at least 5 MMDs
NON-responders will stop mAbs treatment and will receive one of the following:
* PEA supplementation (600mg twice a day for three months)
* ketogenic diet (KD) for three months (characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates)
Partial responders will be assigned to add-on to mAbs:
\- PEA (600mg twice a day for three months)
Clinical data will be collected and biochemical and neurofunctional profiling of migraine patients will be performed before starting novel treatment (PEA or KD) (V0) and after three months of treatment (V1). Clinical data will be collected up to 6 months from treatment starting (V2).
Methods:
BIOCHEMICAL PROFILING
All patients will undergo a biochemical profiling that will include analysis of:
* eCBome system: FAAH, MAGL, DAGL, NAPE, NAAA mRNA in PBMCs;
* plasma levels of AEA, 2-AG, PEA and OEA; CGRP, PACAP, and VIP; IL-1beta, TNF-alpha, IL-4, and IL-10; kynurenic and quinolinic acids;
* miR-382-5p, miR-34a, miR-30a, and miR-155 in PBMCs;
* shotgun analysis of microbiota in patients' faeces. Biochemical sampling will be collected between 9 and 11 a.m. to avoid circadian rhythm influence. All evaluation will be performed in the interictal phase. All samples will be pre-processed within 30 minutes from blood sampling, and immediately stored at -80° C. The final processing will be performed within 3 months.
The following collection methods will be adopted:
* mRNA of eCBome enzymes and microRNA analysis in PBMCs. Blood samples will be collected within ethylenediamine tetra-acetic acid tubes, with isolation of PBMCs and total RNA. Ubiquitin C and U6 will act as housekeeping genes for genes coding for the eCBome enzymes and miRNAs.
* Endocannabinoids and related lipids extraction; kynurenic acid and quinolinic acid, AEA, PEA, 2-AG and OEA will be determined according to the method published by Gao and collaborators with minor modifications(Gao, 2020). Measurement of kinurenine metabolite levels will be performed according to the method described by Fuertig et al. with minor modifications (Fuertig, 2016).
* Plasma samples will be prepared by centrifugation of blood samples. CGRP alpha, PACAP-38 and VIP levels will be measured using a commercial enzyme linked immunosorbent assay; while IL-1beta, TNF-alpha, IL-4, IL-10 cytokine will be measured by the Ella Automated Immunoassay System with a Simple Plex assay panel.
* Microbiome analysis: patients will be instructed for the correct collection and preservation of stool specimens; these will be delivered to the Translational Neurovascular Research Unit (IRCCS Mondino Foundation) for DNA extraction. DNA samples will be stored at -80°C until shotgun microbiome analysis.
NEUROFUNCTIONAL PROFILING All patients will undergo high density-EEG and subset of 40 patients will also be studied in parallel with resting state- functional MRI at T0.
\- HD-EEG: the investigators will randomly acquire 4 recordings (6 minutes each) in resting-state condition, 2 with opened eyes, and 2 with closed eyes. The following frequency bands will be considered: delta (1-4 Hz), theta (4-8 Hz), alfa (8-13 Hz), beta (13-30 Hz), gamma (30-80 Hz).
Acquisition parameters will be: High-Pass: 0.5 Hz; Low-Pass: 100 Hz; Notch: 50 Hz. For analysis of HD-EEG data, a previously developed and validated tailored analysis pipe-line will be used to reconstruct neural sources from cortical/subcortical gray matter. EEG signals will be band-pass filtered (1-80 Hz) and down-sampled at 250 Hz. Biological artifacts will be rejected using Independent Component Analysis (ICA). EEG signals will be referenced with a customized version of the Reference Electrode Standardization Technique (REST). A matrix will estimate the relationship between the measured scalp potentials and the dipoles corresponding to brain sources. Sources reconstruction will be performed with the exact low-resolution brain electromagnetic tomography (eLORETA) algorithm
Statistical analysis As a pilot study, sample size is not calculated and our data will provide the fundament for further confirmatory randomized controlled studies.
The investigators will separately evaluate the clinical effects of Ketogenic Diet and PEA supplementation in NON-responders and PEA supplementation in partial responders.
As statistical test, ANOVA for repeated measure test, with a within-subject TIME factor (T0 vs. T3 vs. T6) will be used. The primary outcome will be the reduction in MMDs at T3 compared with baseline. As secondary outcome the investigators will analyze: modification of monthly headache days, monthly days of acute drug intake, monthly doses of acute drugs, percentage of patients with a 30-50% reduction of MMDs, migraine related disability (MIDAS, HIT-6), and quality of life (MSQ).
There is therefore room for improvement, and understanding the pathophysiological mechanisms involved in these processes is mandatory to develop novel therapies and optimize treatment outcome.
Among several non-CGRP pathways, the eCBome may play a major role in migraine as it interacts with multiple pathways to modulate inflammation and pain.
Previous evidence showed that genes expression of eCBome system is altered in migraine patients.
Interestingly, it seems possible to normalize eCBome dysfunction in migraineurs, as demonstrated by the decrease of FAAH levels in chronic migraineurs with medication overuse who underwent a successful detoxification.
From a therapeutic point of view, a potential role for PEA in the termination of experimentally-induced migraine attack in humans and in the acute treatment of spontaneous attacks were published.
Polyunsaturated fatty acids (PUFAs) are other eCBome precursors involved in neuronal processes and anti-inflammatory properties. Data supports an interconnection between dietary n-3 PUFAs intake, also showing a protective action of high PUFAs intake in inflammation and neurodegenerative disease.
Another therapeutic weapon is represented by the ketogenic diet (KD), a "fat" diet that induces an increase in PUFAs. In migraine, KD reduced the frequency of migraine attacks when compared to a standard mediterranean diet in episodic migraine.
It may interfere with the eCBome at multiple levels (gut and brain) and via multiple mechanisms: i) increase in substrate availability; ii) improvement of cortical metabolism and hyperexcitability enhancing glutamate clearing from astrocytes; ii) modulation of neuro-inflammation.
Preliminary evidence also support a role for KD in treatment-resistant migraine, and in a small number of CM patients resistant to approved therapies, with preliminary data suggest a positive response. Its efficacy in patients who failed mAbs treatment is yet to be elucidated, though.
As intriguing data suggests the possibility to interfere with the eCBome via multiple modalities, ranging from PEA administration to dietary adaptations, it seems extremely interesting to identify an eCBome-dependent migraine phenotype and to test its performance in proof-of-concept therapeutic challenges.
The investigators intend to act on the alteration of microbiota through the ketogenic diet (KD) and on the alteration in endocannabinoids related lipids with PEA or PUFA supplementation. These therapeutic modalities are already available for clinical use and have a highly safe profile, easily ready to be used for improving health in a group of highly disabled patients.
The investigators will also try a concomitant therapy (mAbs + PEA / PUFA) in order to provide insights on the effect of a concomitant dual modulation (CGRP and eCBome system) in patients undergoing mAbs treatment.
Furthermore, a comprehensive biochemical set of potential biomarkers will be evaluated, including neuropeptides, microRNAs, inflammatory cytokines, kynurenine metabolites and brain cortical connectivity trough recording of HD- EEG and rs-fMRI. The biochemical and functional phenotyping will allow the identification of a multibiomarkers panel signature of migraine patients resisting to specifically targeted preventive treatments, potentially associated to the clinical response to treatments that targets different pathways.
Study design:
Patients will be enrolled among those receiving treatment with monoclonal antibodies against the calcitonin gene receptor peptide pathway (mAbs) at the clinic of IRCCS Mondino Institute (Pavia) and Neurology Department of the University of L'Aquila (Avezzano).
The following groups will be identified:
* NON-responder group: patients who show a reduction \< 50% of MMDs after 3 to 6 months of mAbs treatment compared to baseline
* Partial Responder: patients who show a reduction \> / = 50% of MMDs after 3 to 6 months of treatment compared to baseline, but still having at least 5 MMDs
NON-responders will stop mAbs treatment and will receive one of the following:
* PEA supplementation (600mg twice a day for three months)
* ketogenic diet (KD) for three months (characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates)
Partial responders will be assigned to add-on to mAbs:
\- PEA (600mg twice a day for three months)
Clinical data will be collected and biochemical and neurofunctional profiling of migraine patients will be performed before starting novel treatment (PEA or KD) (V0) and after three months of treatment (V1). Clinical data will be collected up to 6 months from treatment starting (V2).
Methods:
BIOCHEMICAL PROFILING
All patients will undergo a biochemical profiling that will include analysis of:
* eCBome system: FAAH, MAGL, DAGL, NAPE, NAAA mRNA in PBMCs;
* plasma levels of AEA, 2-AG, PEA and OEA; CGRP, PACAP, and VIP; IL-1beta, TNF-alpha, IL-4, and IL-10; kynurenic and quinolinic acids;
* miR-382-5p, miR-34a, miR-30a, and miR-155 in PBMCs;
* shotgun analysis of microbiota in patients' faeces. Biochemical sampling will be collected between 9 and 11 a.m. to avoid circadian rhythm influence. All evaluation will be performed in the interictal phase. All samples will be pre-processed within 30 minutes from blood sampling, and immediately stored at -80° C. The final processing will be performed within 3 months.
The following collection methods will be adopted:
* mRNA of eCBome enzymes and microRNA analysis in PBMCs. Blood samples will be collected within ethylenediamine tetra-acetic acid tubes, with isolation of PBMCs and total RNA. Ubiquitin C and U6 will act as housekeeping genes for genes coding for the eCBome enzymes and miRNAs.
* Endocannabinoids and related lipids extraction; kynurenic acid and quinolinic acid, AEA, PEA, 2-AG and OEA will be determined according to the method published by Gao and collaborators with minor modifications(Gao, 2020). Measurement of kinurenine metabolite levels will be performed according to the method described by Fuertig et al. with minor modifications (Fuertig, 2016).
* Plasma samples will be prepared by centrifugation of blood samples. CGRP alpha, PACAP-38 and VIP levels will be measured using a commercial enzyme linked immunosorbent assay; while IL-1beta, TNF-alpha, IL-4, IL-10 cytokine will be measured by the Ella Automated Immunoassay System with a Simple Plex assay panel.
* Microbiome analysis: patients will be instructed for the correct collection and preservation of stool specimens; these will be delivered to the Translational Neurovascular Research Unit (IRCCS Mondino Foundation) for DNA extraction. DNA samples will be stored at -80°C until shotgun microbiome analysis.
NEUROFUNCTIONAL PROFILING All patients will undergo high density-EEG and subset of 40 patients will also be studied in parallel with resting state- functional MRI at T0.
\- HD-EEG: the investigators will randomly acquire 4 recordings (6 minutes each) in resting-state condition, 2 with opened eyes, and 2 with closed eyes. The following frequency bands will be considered: delta (1-4 Hz), theta (4-8 Hz), alfa (8-13 Hz), beta (13-30 Hz), gamma (30-80 Hz).
Acquisition parameters will be: High-Pass: 0.5 Hz; Low-Pass: 100 Hz; Notch: 50 Hz. For analysis of HD-EEG data, a previously developed and validated tailored analysis pipe-line will be used to reconstruct neural sources from cortical/subcortical gray matter. EEG signals will be band-pass filtered (1-80 Hz) and down-sampled at 250 Hz. Biological artifacts will be rejected using Independent Component Analysis (ICA). EEG signals will be referenced with a customized version of the Reference Electrode Standardization Technique (REST). A matrix will estimate the relationship between the measured scalp potentials and the dipoles corresponding to brain sources. Sources reconstruction will be performed with the exact low-resolution brain electromagnetic tomography (eLORETA) algorithm
Statistical analysis As a pilot study, sample size is not calculated and our data will provide the fundament for further confirmatory randomized controlled studies.
The investigators will separately evaluate the clinical effects of Ketogenic Diet and PEA supplementation in NON-responders and PEA supplementation in partial responders.
As statistical test, ANOVA for repeated measure test, with a within-subject TIME factor (T0 vs. T3 vs. T6) will be used. The primary outcome will be the reduction in MMDs at T3 compared with baseline. As secondary outcome the investigators will analyze: modification of monthly headache days, monthly days of acute drug intake, monthly doses of acute drugs, percentage of patients with a 30-50% reduction of MMDs, migraine related disability (MIDAS, HIT-6), and quality of life (MSQ).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Migraine Disorders
Chronic Migraine
Episodic Migraine
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
CASE_CONTROL
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NON-Responders
Patients with high frequency episodic or chronic migraine who obtained a reduction in monthly migraine days \< 50% after three months of mAbs treatment compared to pre-treatment values.
Palmitoyl ethanolamide
Intervention Type
DIETARY_SUPPLEMENT
PEA supplementation (600mg twice a day for three months)
Ketogenic diet
Intervention Type
BEHAVIORAL
Diet characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates
Partial-Responders
Patients with high frequency episodic or chronic migraine who obtained a reduction in monthly migraine days \> or equal to 50% after six months of mAbs treatment compared to pre-treatment values but still present more than 5 MMDs.
Palmitoyl ethanolamide
Intervention Type
DIETARY_SUPPLEMENT
PEA supplementation (600mg twice a day for three months)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Palmitoyl ethanolamide
PEA supplementation (600mg twice a day for three months)
Intervention Type
DIETARY_SUPPLEMENT
Ketogenic diet
Diet characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates
Intervention Type
BEHAVIORAL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
PEA
KD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* male and female patients aged 18 to 75 years
* diagnosis of episodic migraine or chronic migraine according to ICHD-3 criteria
* for episodic migraine: 8-14 monthly migraine days in the previous 3 months
* diagnosis of resistant migraine, defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating monthly headache days for at least 3 consecutive months
* patients naive to CGRP targeting treatments
* diagnosis of episodic migraine or chronic migraine according to ICHD-3 criteria
* for episodic migraine: 8-14 monthly migraine days in the previous 3 months
* diagnosis of resistant migraine, defined by having failed at least 3 classes of migraine preventatives and suffer from at least 8 debilitating monthly headache days for at least 3 consecutive months
* patients naive to CGRP targeting treatments
Exclusion Criteria
* history of major psychiatric or other neurological conditions
* diagnosis of other primary or secondary headache disorders (only sporadic tension-type headache is allowed if the patients can clearly differentiate between the 2 types of headaches)
* clinically significant medical conditions
* chronic pain conditions
* alcohol and/or drug abuse
* pregnancy or lactation
* diagnosis of other primary or secondary headache disorders (only sporadic tension-type headache is allowed if the patients can clearly differentiate between the 2 types of headaches)
* clinically significant medical conditions
* chronic pain conditions
* alcohol and/or drug abuse
* pregnancy or lactation
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of L'Aquila
OTHER
Sponsor Role
collaborator
IRCCS National Neurological Institute "C. Mondino" Foundation
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Headache Science & Neurorehabilitation Unit
Pavia, , Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Greco R, Demartini C, Zanaboni AM, Tumelero E, Icco R, Sances G, Allena M, Tassorelli C. Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study. Cephalalgia. 2021 Feb;41(2):185-196. doi: 10.1177/0333102420949201. Epub 2020 Sep 23.
Reference Type
BACKGROUND
De Icco R, Greco R, Demartini C, Vergobbi P, Zanaboni A, Tumelero E, Reggiani A, Realini N, Sances G, Grillo V, Allena M, Tassorelli C. Spinal nociceptive sensitization and plasma palmitoylethanolamide levels during experimentally induced migraine attacks. Pain. 2021 Sep 1;162(9):2376-2385. doi: 10.1097/j.pain.0000000000002223.
Reference Type
BACKGROUND
de Almeida Rabello Oliveira M, da Rocha Ataide T, de Oliveira SL, de Melo Lucena AL, de Lira CE, Soares AA, de Almeida CB, Ximenes-da-Silva A. Effects of short-term and long-term treatment with medium- and long-chain triglycerides ketogenic diet on cortical spreading depression in young rats. Neurosci Lett. 2008 Mar 21;434(1):66-70. doi: 10.1016/j.neulet.2008.01.032. Epub 2008 Jan 19.
Reference Type
BACKGROUND
Bongiovanni D, Benedetto C, Corvisieri S, Del Favero C, Orlandi F, Allais G, Sinigaglia S, Fadda M. Effectiveness of ketogenic diet in treatment of patients with refractory chronic migraine. Neurol Sci. 2021 Sep;42(9):3865-3870. doi: 10.1007/s10072-021-05078-5. Epub 2021 Feb 1.
Reference Type
BACKGROUND
Di Lorenzo C, Coppola G, Sirianni G, Di Lorenzo G, Bracaglia M, Di Lenola D, Siracusano A, Rossi P, Pierelli F. Migraine improvement during short lasting ketogenesis: a proof-of-concept study. Eur J Neurol. 2015 Jan;22(1):170-7. doi: 10.1111/ene.12550. Epub 2014 Aug 25.
Reference Type
BACKGROUND
Paulus MP, Stein MB, Simmons AN, Risbrough VB, Halter R, Chaplan SR. The effects of FAAH inhibition on the neural basis of anxiety-related processing in healthy male subjects: a randomized clinical trial. Neuropsychopharmacology. 2021 Apr;46(5):1011-1019. doi: 10.1038/s41386-020-00936-w. Epub 2020 Dec 17.
Reference Type
BACKGROUND
Deng H, Li W. Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders. Acta Pharm Sin B. 2020 Apr;10(4):582-602. doi: 10.1016/j.apsb.2019.10.006. Epub 2019 Oct 18.
Reference Type
BACKGROUND
Chirchiglia D, Cione E, Caroleo MC, Wang M, Di Mizio G, Faedda N, Giacolini T, Siviglia S, Guidetti V, Gallelli L. Effects of Add-On Ultramicronized N-Palmitol Ethanol Amide in Patients Suffering of Migraine With Aura: A Pilot Study. Front Neurol. 2018 Aug 17;9:674. doi: 10.3389/fneur.2018.00674. eCollection 2018.
Reference Type
BACKGROUND
Papetti L, Sforza G, Tullo G, Alaimo di Loro P, Moavero R, Ursitti F, Ferilli MAN, Tarantino S, Vigevano F, Valeriani M. Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study. Pain Res Manag. 2020 Apr 24;2020:3938640. doi: 10.1155/2020/3938640. eCollection 2020.
Reference Type
BACKGROUND
Freitas HR, Isaac AR, Malcher-Lopes R, Diaz BL, Trevenzoli IH, De Melo Reis RA. Polyunsaturated fatty acids and endocannabinoids in health and disease. Nutr Neurosci. 2018 Dec;21(10):695-714. doi: 10.1080/1028415X.2017.1347373. Epub 2017 Jul 7.
Reference Type
BACKGROUND
Perrotta A, Arce-Leal N, Tassorelli C, Gasperi V, Sances G, Blandini F, Serrao M, Bolla M, Pierelli F, Nappi G, Maccarrone M, Sandrini G. Acute reduction of anandamide-hydrolase (FAAH) activity is coupled with a reduction of nociceptive pathways facilitation in medication-overuse headache subjects after withdrawal treatment. Headache. 2012 Oct;52(9):1350-61. doi: 10.1111/j.1526-4610.2012.02170.x. Epub 2012 Jun 1.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SPHERA - WP2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Role of Specific microRNAs in Cluster Headache
NCT06503328
RECRUITING
Th Effect of Ketogenic Metabolic Nutritional Pattern on High-frequency Episodic Migraine (EMIKETO)
NCT04360148
UNKNOWN
NA
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients
NCT04324710
COMPLETED
Very Low Calories Ketogenic Diet in Migraine.
NCT03076060
COMPLETED
NA
HD-EEG Connectivity Changes in Migraine Patients Undergoing Treatment With Anti-CGRP mAbs
NCT06155123
RECRUITING
Nutrition for Migraine Prevention
NCT02012790
COMPLETED
NA
A Ketogenic Diet Acts on Cortical But Not Subcortical Responsivity in Migraineurs
NCT03775252
COMPLETED
NA
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies
NCT04503083
UNKNOWN
Calcitonin Gene-related Peptide in Familial Hemiplegic Migraine (FHM) and Migraine With Aura (MA)
NCT00687947
COMPLETED
NA
A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)
NCT01513291
COMPLETED
PHASE2
Transcranial Direct Current Stimulation Plus Monoclonal Antibodies Acting on the CGRP Pathway for Migraine
NCT05161871
COMPLETED
NA
Ketamine + Magnesium for Chronic Cluster Headache (KETALGIA)
NCT04814381
RECRUITING
PHASE4
Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine
NCT06882122
RECRUITING
Calcitonin Gene Related Peptide-Induced Headache in Patients With Familial Hemiplegic Migraine Type 1 and 2.
NCT00358839
COMPLETED
NA
The Evolution and Management of Migraine Recurrence Beyond 24 Hours
NCT00754611
COMPLETED
Nutritional Intervention in Migraine
NCT02703129
COMPLETED
NA
Efficacy of OnabotulinumtoxinA in Migraine
NCT04578782
COMPLETED
PHASE2
Treatment of Episodic Migraine With AURICular Neuromodulation
NCT06623188
RECRUITING
NA
The Role of CGRPand Nociceptin in Migraine
NCT00155129
UNKNOWN
Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: a Prospective Case Series
NCT03244735
COMPLETED
NA
Effect of Acetyl-L-carnitine in Migraine
NCT01695317
COMPLETED
PHASE4
Neuro-Complex & Multi Supplements for Migraine Prevention
NCT07015411
RECRUITING
NA
Efficacy and Safety of Stellate Ganglion Block With Lidocaine Combined Platelet-rich Plasma to Treat Chronic Migraine
NCT06653218
RECRUITING
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479
RECRUITING
PHASE2
Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1
NCT06462781
COMPLETED
PHASE1